AXON Axovant Sciences Ltd. Common Sh

12.22
-0.29  -2.25%
Previous Close 12.50
Open 12.46
Price To book 6.02
Market Cap 1.21B
Shares 99,161,000
Volume 173,720
Short Ratio 15.90
Av. Daily Volume 263,665

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 2 data due 2H 2017.
Nelotanserin
DLB patients experiencing REM Behavior Disorder (RBD)
Phase 2b data due 4Q 2017
Intepirdine - HEADWAY-DLB
Dementia with Lewy bodies (DLB)
Phase 2 data due February 2017.
Nelotanserin
Visual hallucinations in subjects with Lewy body dementia
Phase 3 data are due 3Q 2017.
Intepirdine - MINDSET
Alzheimer’s disease

Latest News

  1. AXOVANT SCIENCES LTD. Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements and Exh
  2. Axovant Sciences Announces Pipeline Program Updates and Presentation at 35th Annual J.P. Morgan Conference
  3. Implied Volatility Surging for Axovant Sciences (AXON) Stock Options
  4. Coverage initiated on Axovant Sciences by Laidlaw
  5. Axovant Unveils New Data Analysis Showing Addition of Intepirdine to Standard Therapy May Help People with Alzheimer's Disease Maintain Independence Longer
  6. Is Axovant Sciences Ltd (AXON) Worthy of Your Portfolio?
  7. Axovant to Present Patient Function and Independence Data Analyses from Phase 2b Study of Investigational Treatment Intepirdine in Alzheimer's Disease at CTAD 2016
  8. Axovant Sciences Ltd. :AXON-US: Earnings Analysis: Q2, 2017 By the Numbers : November 28, 2016
  9. Will Lilly's Solanezumab Setback Weigh on Other Alzheimer's Stocks?
  10. Eli Lilly's Alzheimer's Drug Is a Bust
  11. Five Lessons From Today's Pharma Failures
  12. Trending Stocks: First Solar, Inc. (FSLR), Eli Lilly and Co (LLY), and More
  13. AXOVANT SCIENCES LTD. Financials
  14. Can Small-Cap Biotech Take On Gilead, Celgene, Biogen In Alzheimer's?
  15. AXOVANT SCIENCES LTD. Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements and Exh
  16. Axovant Sciences Announces Dementia Pipeline Updates and Reports Financial Results for the Second Fiscal Quarter and First Half Ended September 30, 2016
  17. Axovant Sciences to Present at Upcoming Investor Conferences
  18. Axovant Sciences to Present at Upcoming Investor Conferences
  19. Biggest Biotech IPO Of 2016 Is Launched By 31 Year Old
  20. Ligand Partner Melinta Therapeutics Submits NDA for Baxdela